Radiotherapy plays a critical role in the definitive management of early stage and locally advanced non- small cell lung cancer (NSCLC), the number one cause of cancer deaths in the United States. Two important challenges in the management of NSCLC patients treated with radiotherapy are the inability to detect microscopic residual disease and the difficulty of distinguishing between recurrent malignancy and post-radiation normal tissue changes on follow-up radiographic studies. These shortcomings prevent design and testing of individualized treatment strategies that could potentially increase cure rates and suggest that improved methods for following patients after treatment are needed. Our goal is to test a novel approach for detecting the presence of residual or recurrent disease in NSCLC patients treated with radiotherapy. Somatic alterations in the genomes of cancer cells represent ideal biomarkers, since they can define patient- and tumor-specific signatures that distinguish cancer cells from non-malignant counterparts. Cancers continually release genomic DNA into the circulation, potentially allowing noninvasive access to cancer genomes and quantitation of disease burden. We have designed and implemented a novel, high throughput sequencing-based technique for measurement of circulating tumor-derived DNA termed CAPP- Seq (CAncer Personalized Profiling in by deep Sequencing). We propose to evaluate the utility of ctDNA analysis via CAPP-Seq in NSCLC patients treated with radiotherapy and to explore mechanisms of ctDNA release and clearance in human patients. Taken together, these studies will lay the groundwork for prospective clinical trials that will test personalization of radiotherpy-based therapeutic strategies using ctDNA analysis.

Public Health Relevance

Lung cancer is the leading cause of cancer death and radiation therapy is often used to treat patients with the disease. Currently, there is no reliable method to identify which patients have been cured by treatment and which have residual disease. We have devised a method to address this problem and will test it in lung cancer patients treated with radiation therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA188298-02
Application #
9070751
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Bernhard, Eric J
Project Start
2015-06-01
Project End
2020-05-31
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Przybyl, Joanna; Chabon, Jacob J; Spans, Lien et al. (2018) Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. Clin Cancer Res 24:2688-2699
Dudley, Jonathan C; Schroers-Martin, Joseph; Lazzareschi, Daniel V et al. (2018) Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discov :
Kurtz, David M; Scherer, Florian; Jin, Michael C et al. (2018) Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol 36:2845-2853
Harris, Jeremy P; Patel, Manali I; Loo, Billy W et al. (2017) A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. Lung Cancer 108:173-182
Jeong, Youngtae; Hoang, Ngoc T; Lovejoy, Alexander et al. (2017) Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discov 7:86-101
Scherer, Florian; Kurtz, David M; Diehn, Maximilian et al. (2017) High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood 130:440-452
Chaudhuri, Aadel A; Chabon, Jacob J; Lovejoy, Alexander F et al. (2017) Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov 7:1394-1403
Newman, Aaron M; Lovejoy, Alexander F; Klass, Daniel M et al. (2016) Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 34:547-555
Scherer, Florian; Kurtz, David M; Newman, Aaron M et al. (2016) Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 8:364ra155
Chabon, Jacob J; Simmons, Andrew D; Lovejoy, Alexander F et al. (2016) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815

Showing the most recent 10 out of 13 publications